• The new ESC 2020 guidelines

    The annual ESC congress recorded four new or updated guidelines. We report some key points related to the management of non-ST segment elevation acute coronary syndromes.

  • SGLT2 inhibitors in cardiology: A therapeutic breakthrough

    The current hype around SGLT2 inhibitors in the treatment of heart failure patients is more than justified, according to Prof. Martin Cowie

  • Drug launch strategy: no rise in oral anticoagulants use

    An educational program for patients with atrial fibrillation and their healthcare providers did not result in more oral anticoagulants being administered after one year than with the usual treatment

  • PCI: Trimetazidine does not lead to fewer cardiac events

    Patients under successful PCI for angina pectoris and acute coronary syndrome without ST elevation have good long-term results with optimal medical therapy. In the ATPCI study, the routine use of trimetazidine did not lead to a reduction in cardiac events in this patient group.

  • Acute MI: Restrictive transfusion strategy is superior to a liberal strategy

    Restrictive blood transfusion has no negative impact on clinical outcomes compared to more liberal strategies in anemic patients with acute MI. Restrictive strategies resulted in fewer infections and acute lung injuries.

  • Thromboembolism and bleeding: Lessons from Wuhan

    An evaluation of COVID-19 patients admitted to a Wuhan hospital shows that they were at high risk of thromboembolic events and bleeding, as well as an increased risk of mortality.

  • SGLT2 inhibitors in cardiological practice

    Modern antidiabetics, such as SGLT2 inhibitors, have shown positive effects on cardiovascular risks or kidney function for diabetics. However, recent study results show an equal benefit for heart failure patients regardless of their diabetes status.

  • The heart versus COVID-19: Lessons from the crisis

    Prof. Casadei talks about what the cardiology field has learnt from the COVID-19 crisis, what positive aspects have emerged from it, and how to turn the profession back into a vocation.

  • Early rhythm control improves cardiovascular outcomes

    The early practice of rhythm control reduces cardiovascular outcomes in patients with early atrial fibrillation and comorbid cardiovascular conditions compared to current evidence-based standard care.

  • SGLT2 inhibitors improve risk in heart failure

    Recent studies on heart failure treatment showed that SGLT2 inhibitors reduced the risk of cardiovascular death or even hospitalization in heart failure, with reduced ejection fraction compared to placebo.

  • Cardiovascular risk in diabetes

    The cardiovascular risk in diabetes is determined by some comorbidities. Renal dysfunction and micro- and macrovascular events are common. Should diabetes patients be screened for cardiovascular risks?

  • Using physical training against cardiotoxicity

    Tumour treatment with drugs often leads to a rapid loss of strength in patients and increases their cardiovascular risk and general mortality. Accompanying physical training can mitigate these effects.

  • Austria: New antibody for anemia therapy developed

    A research team developed an innovative antibody for chronic anemia treatment in dialysis patients. It allows for a lower EPO dose and the resulting minimization of cardiovascular risk.

  • Yoga improves symptoms of atrial fibrillation

    According to a recent study, the movements and breathing during yoga have a positive influence on the symptoms in patients with atrial fibrillation.

  • Selfies reveal cardiovascular risks

    Just send a selfie to the cardiologist and receive a heart disease risk assessment. Sounds futuristic? It could actually become routine, according to a recent study.

  • Research looks at intestinal flora damage and strokes

    Dr. Vikramjeet Singh is investigating how the interaction of intestinal bacteria and immune cells influences a brain infarction, with a particular focus on microbial diversity in the intestine, and neutrophils.

  • HCV eradication within reach

    Hepatitis-C eradication by 2030, as required by the WHO, is within reach in Spain. Dr. Joaquin Cabezas explains how the country is making prisons HCV-free by near 100% diagnosis and 100% treatment.

  • Non-alcoholic fatty liver: MSR1 mediates lipid-induced inflammation

    NAFLD is a form of fatty liver (steatosis hepatitis) not caused by increased alcohol consumption. The prevalence in Europe is estimated to be between 20 and 30%.

  • Antimicrobial basalt: From rocks to threads

    Scientists have developed effective antimicrobial glass and basalt fibers. The fibers are effective against different strains of bacteria and fungi and might be used in filters and textiles in the future.

  • Primary care AST-testing for chronic liver disease detection

    Chronic liver disease is on the rise. Aside from undetected liver disease, abnormal liver function tests are often not followed up in primary care, or many patients ignore their follow-up appointments.

  • 19 |
  • 20 |
  • 21 |
  • 22 |
  • 23 |
  • 24 |
  • 25 |
  • 26 |
  • 27 |
  • 28 |
  • 29 |